Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
NCT06169215
Recruiting
This phase II trial compares the combination of selinexor, daratumumab and hyaluronidase-fihj (daratumumab), velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVD) in treating patients with high-risk newly diagnosed multiple myeloma. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growin... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/24/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Multiple Myeloma
Register for Updates
A User-friendly, Non-invasive Neuro-orthosis That Restores Volitionally Controlled Grasp Functions for SCI Survivors With Tetraplegia
NCT06087445
Recruiting
The goal of this pilot clinical study is to investigate the NeuroLife EMG-FES Sleeve System, a closed-loop approach to functional electrical stimulation, in adults (n=12) with chronic (\>12 months) tetraplegia due to spinal cord injury. Briefly, the NeuroLife EMG-FES System is a completely non-invasive system (surface electrodes only, no implantable components) worn on the forearm which has up to 160 electrodes that can record electromyography (EMG), or muscle activity, and also electrically sti... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/24/2025
Locations: Battelle Memorial Institute, Columbus, Ohio
Conditions: Cervical Spinal Cord Injury
Register for Updates
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850
Recruiting
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/24/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613
Recruiting
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Register for Updates
Increased Home-based Physical Therapy Adherence Using BAND Connect's VirtuaCare™ Platform
NCT05876208
Recruiting
This study aims to enhance at-home therapy by introducing a new device called the BAND Connect's VirtuaCare™ platform. The study aims to determine whether patients can improve their adherence to at-home exercises using this device. Currently, research indicates that only 35% of patients undergoing physical therapy treatment fully comply with their prescribed plans of care, often neglecting their at-home exercises. To address this issue, a set of smart exercise tools called VirtuaCare™ has been d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Shoulder Injuries
Register for Updates
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244
Recruiting
Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and t... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/24/2025
Locations: OSU Wexner Medical Center, Columbus, Ohio
Conditions: Acute Ischemic Stroke, Cerebral Stroke
Register for Updates
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT05498272
Recruiting
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic select HRR alterations. Germline and somatic mutation testing will be performed as part of commercially available CLIA assays and will be validated on a uniform platform centrally all... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Register for Updates
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
NCT05364502
Recruiting
To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Arterial Bleeding in Solid Organs and Peripheral Arteries
Register for Updates
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216
Recruiting
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unl... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/24/2025
Locations: Miami Valley Hospital, Dayton, Ohio
Conditions: Acute Stroke, Ischemic Stroke, Stroke
Register for Updates
International CIPN Assessment and Validation Study
NCT04633655
Recruiting
This is an observational study of chemotherapy-induced peripheral neurotoxicity (CIPN) patients to be investigated prospectively in order to assess responsiveness of a set of outcome measures in an international multi-center study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Cancer Center/Wexner Medical Center - Ohio State Medical Oncology Division, Columbus, Ohio
Conditions: Chemotherapy-induced Peripheral Neuropathy, Quality of Life
Register for Updates
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Oncology Hematology Care Clinical Trials, Cincinnati, Ohio
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Register for Updates
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
NCT04301076
Recruiting
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
Register for Updates